Plasma cell neoplasm
Also known as plasma cell dyscrasia, plasma cell tumor, plasma cell tumor, malignant, plasma cell tumour+4 more
plasma cell dyscrasia, plasma cell tumor, plasma cell tumor, malignant, plasma cell tumour, plasmacytic neoplasm, plasmacytic tumor, plasmacytic tumour, plasma cell disorder.
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2026-06-02ClinicalA Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological DisordersResults posted
- 2026-04-15ClinicalPhase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple MyelomaResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
plasma cell dyscrasia, plasma cell tumor, plasma cell tumor, malignant, plasma cell tumour, plasmacytic neoplasm, plasmacytic tumor, plasmacytic tumour, plasma cell disorder
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.